Intraosseus (IO) naloxone
ApprovedSmall molecule
Intraosseus (IO) naloxone is one of 16 small molecule programs targeting Overdose. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
23 competitors in Overdose
#DrugCompanyPhaseTrials
1Narcan
SScienture
Approved
Suboxone
IIndivior Inc.
Approved
Haldol
DDePuy Orthopaedics
Phase 2
Ativan
BBausch Health Americas, Inc.
Phase 2
Intraosseus (IO) naloxone
JJudith Feinberg
Approved
Cysteine Hydrochloride
NovartisPhase 1
Acetadote
AArbor Pharmaceuticals, Inc.
Phase 1
Naloxone Intranasal
NNorwegian University of Science and Technology
Phase 3
Sublocade
IIndivior Inc.
Phase 3
Intravenous
IIsfahan University of Medical Sciences
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intraosseus (IO) naloxone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- JJudith Feinberg